Posted On: 08/25/2015 8:22:15 AM
Post# of 30034
Let's not forget that Jason Napadano was encouraged by the MSPrecise purchase when it happened. His conclusion:
Conclusion
We believe MSPrecise® is a good fit for Amarantus and will serve as a solid foundation upon which to build a successful diagnostics business. As we mentioned in our “15 Biotech Name for 2015” article, Amarantus has been discussing the possibility of spinning out LymPro into a separately traded diagnostic division in 2015. In the article we state that the company would need to package LymPro with another diagnostic product in CNS, and we believe that MSPrecise® certainly fits the criteria. At this point, we would not be surprised to see the spin-out of Amarantus Diagnostics sometime in the next six months, a move we feel could unlock significant value for shareholders.
http://scr.zacks.com/News/Press-Releases/Pres...fault.aspx
Conclusion
We believe MSPrecise® is a good fit for Amarantus and will serve as a solid foundation upon which to build a successful diagnostics business. As we mentioned in our “15 Biotech Name for 2015” article, Amarantus has been discussing the possibility of spinning out LymPro into a separately traded diagnostic division in 2015. In the article we state that the company would need to package LymPro with another diagnostic product in CNS, and we believe that MSPrecise® certainly fits the criteria. At this point, we would not be surprised to see the spin-out of Amarantus Diagnostics sometime in the next six months, a move we feel could unlock significant value for shareholders.
http://scr.zacks.com/News/Press-Releases/Pres...fault.aspx
(0)
(0)Scroll down for more posts ▼
